Vol. 4 No. 7 (2024)
Reimbursement Reviews

Cannabidiol (Epidiolex)

decorative image of the issue cover

Published July 23, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cannabidiol (Epidiolex), 100 mg/mL, oral solution.
  • Indication: Cannabidiol is indicated for use as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome or tuberous sclerosis complex in patients 2 years of age and older.